Unicycive (UNCY) news
Recent news
UniCycive Therapeutics appoints Meredith Manning to board of directors
UniCycive Therapeutics (UNCY) has announced the appointment of Meredith Manning to its board of directors, as disclosed in a recent SEC filing . The addition of Manning, a seasoned executive with extensive experience in the biopharmaceutical industry, is expected to strengthen the company’s…
AInvest Wire · Oct 1, 2026Unicycive Therapeutics, Inc.: H.C. Wainwright cuts target price to $13 from $15
On June 30, 2026, H.C. Wainwright & Co. revised its target price for Unicycive Therapeutics, Inc. (UNCY) from $15 to $13, while maintaining its "Buy" rating for the stock. This adjustment reflects a 233.33% potential growth from the updated target price, based on the firm’s current valuation…
AInvest Wire · Sep 29, 2026UniCycive Therapeutics resubmits oxylanthanum carbonate NDA
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) announced on July 1, 2026, that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for oxylanthanum carbonate (OLC), an investigational treatment for…
AInvest Wire · Sep 29, 2026Unicycive Therapeutics - FDA inspection of original manufacturing vendor assigned but not completed as of Sept 29, 2026
AInvest Wire · Sep 29, 2026Unicycive Therapeutics - FDA acceptance of NDA expected within 30 days; new PDUFA date in 6 months
AInvest Wire · Sep 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.